Literature DB >> 5343886

Increased oncogenic effect of methylcholanthrene after treatment with anti-lymphocyte serum.

H Balner, H Dersjant.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 5343886     DOI: 10.1038/224376a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  8 in total

1.  The role of the immune response in oncogenesis.

Authors:  H F Jeejeebhoy
Journal:  In Vitro       Date:  1975 May-Jun

2.  Prolonged administration of antithymocyte serum in mice. II. Histopathological investigation.

Authors:  E Simpson; S L Nehlsen
Journal:  Clin Exp Immunol       Date:  1971-07       Impact factor: 4.330

3.  The effects of surgery on lymphocyte transformation in patients with cancer.

Authors:  S M Watkins
Journal:  Clin Exp Immunol       Date:  1973-05       Impact factor: 4.330

4.  Autoimmunity and tumor resistance. 3-Methylcholanthrene tumorigenesis in New Zealand Black mice.

Authors:  J I Morton; B V Siegel; R D Moore
Journal:  Am J Pathol       Date:  1978-11       Impact factor: 4.307

5.  [Immunology of cancer].

Authors:  E Grundmann
Journal:  Langenbecks Arch Chir       Date:  1971-12

Review 6.  Immunosuppression and neoplasia. II. Is deficient immunesurveillance the only mechanism by which immunosuppression promotes neoplasia? A speculative review.

Authors:  E Gleichmann; H Gleichmann
Journal:  Klin Wochenschr       Date:  1973-03-15

7.  New aspects of intestinal carcinogenesis by 1,2-dimethylhydrazine dihydrochloride (DMH) and the influence of antilymphocyte globuline (ALG) on its progress.

Authors:  K Nomura; W Schlake; E Grundmann
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1978-08-24

8.  Heterologous antilymphocyte serum hastens the growth of 7,12-dimethylbenz(alpha)anthracene induced tumours in mice.

Authors:  C D Baroni; R Scelsi; M L Peronace; S Uccini
Journal:  Br J Cancer       Date:  1973-09       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.